Bio-Rad launches Annexin V StarBright conjugates
Aug. 7, 2024—Bio-Rad Laboratories has launched annexin V conjugated to eight StarBright dyes—SBUV400, SBUV795, SBV440, SBV515, SBV790, SBB675, SBB765, and SBY800.
Webinars and Sponsored Roundtables — Register Now
Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.
Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications.
Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Industry News
Adaptimmune gets FDA accelerated approval for Tecelra
Aug. 5, 2024—Adaptimmune Therapeutics announced FDA accelerated approval for Tecelra (afamitresgene autoleucel) for the treatment of adults with unresectable or metastatic synovial sarcoma who have received prior chemotherapy, are HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive, and whose tumor expresses the MAGE-A4 antigen as determined by FDA-approved or -cleared companion diagnostic devices.
FDA approves Guardant’s Shield blood test for CRC
July 29, 2024—Guardant Health announced FDA approval of the company’s Shield blood test for colorectal cancer screening in adults age 45 and older who are at average risk for the disease.
BioPorto to unveil FDA-cleared NGAL test at ADLM
July 23, 2024—BioPorto Diagnostics will unveil its ProNephro AKI (NGAL) test at ADLM 2024, July 28–Aug. 1, in Chicago.
Diasorin gets de novo grant for Simplexa C. auris Direct
July 17, 2024—Diasorin announced that the FDA has granted de novo authorization for the Simplexa C. auris Direct kit to test patients suspected of Candida auris colonization and aid in preventing potential spread in health care settings.
T-Neuro Pharma research article published in PNAS
July 16, 2024—T-Neuro Pharma announced the publication of a landmark research article in Proceedings of the National Academy of Sciences (Panwar A, et al. Proc Natl Acad Sci USA. 2024;121(29):e2401420121).
Thermo Fisher, NCI partner on myeloMATCH umbrella trial
July 12, 2024—Thermo Fisher Scientific is partnering with the National Cancer Institute on the myeloMATCH (Molecular Analysis for Therapy Choice) precision medicine umbrella trial to help accelerate research into new treatments for acute myeloid leukemia and myelodysplastic syndrome.
Cepheid Xpert HCV gets FDA authorization, waiver
July 2, 2024—Cepheid has received FDA de novo marketing authorization and CLIA waiver approval for its Xpert HCV, the first point-of-care hepatitis C RNA test.
TechLab C. diff test receives European IVDR certification
July 1, 2024—TechLab, a part of SSI Diagnostica Group, announced that its C. Diff Quik Chek Complete test has received certification under European in vitro diagnostic medical device regulation.
Siemens offers NT‑proBNPII assay on Atellica Solution
June 28, 2024—Siemens Healthineers has added the NT‑proBNPII assay to its cardiac test menu on the Atellica Solution to help diagnose heart failure.